Articles
| Open Access |
DOI:
https://doi.org/10.37547/ijmscr/Volume05Issue02-07
Results of immunogystochemic study in primary liver cancer developed on the basis of chronic viral hepatitis
Musaboev E.I , Republican Specialized Scientific and Practical Medical Center of Virology, Tashkent, Uzbekistan Abdikhakimov A.N , Tashkent Regional Branch of the Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology, Tashkent, Uzbekistan Mirzaev Kh.M , Center for the Development of Professional Qualifications of Medical Workers, Tashkent, Uzbekistan Gafur-Akhunov M.A , Center for the Development of Professional Qualifications of Medical Workers, Tashkent, Uzbekistan Nishanov D.A , Republican Specialized Scientific and Practical Medical Center of Pathological Anatomy, Tashkent, Uzbekistan Yigitaliyev A.B , Fergana Medical Institute of Public Health, Fergana, UzbekistanAbstract
This article is devoted to immunohistochemical studies associated with primary liver cancer (hepatocellular carcinoma - HCC) developed against the background of chronic viral hepatitis B, C. The topic is relevant, since HCC is one of the aggressive tumors with a high mortality rate, arising as a result of chronic hepatitis B and C, alcoholic or non-alcoholic fatty liver diseases. The study included 30 patients examined in 2020-2023, all of whom were diagnosed with viral hepatitis B or C. In the immunohistochemical study, molecular genetic markers (Ki-67, Bcl-2, VEGF, and p53) were studied. According to the results, in cases of HCC associated with viral hepatitis, high proliferative activity (Ki-67 >20%), apoptosis index (Bcl-2), angiogenesis activity (VEGF), and p53 gene suppressor mutations were observed more often. Molecular-genetic markers in primary liver cancer are important in assessing the aggressiveness of the tumor, the degree of metastasis, and the response to treatment. The research results open up new possibilities for improving the diagnosis, prognosis, and personalized therapy strategies for HCC.
Keywords
Hepatocellular carcinoma, p53 gene suppressor, immunohistochemical examination
References
Bruix, J., Reig, M., & Sherman, M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology, 2019. 156(2), 411–421. https://doi.org/10.1053/j.gastro.2018.08.065
Craig, A. J., von Felden, J., Garcia-Lezana, T., Sarcognato, S., & Villanueva, A. Tumour evolution in hepatocellular carcinoma. Nature Reviews Gastroenterology & Hepatology, 2020. 17(3), 139–152. https://doi.org/10.1038/s41575-019-0229-4
El-Serag, H. B., & Rudolph, K. L. Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology, 2017. 132(7), 2557–2576. https://doi.org/10.1053/j.gastro.2017.02.063
Fan, B., Malato, Y., Calvisi, D. F., Sun, H. C., & Wang, X. W. Ki-67 expression as a prognostic marker in hepatocellular carcinoma. BMC Cancer, 2020. 20(1), 1123. https://doi.org/10.1186/s12885-020-07620-2
Faivre, S., Rimassa, L., & Finn, R. S. Molecular therapies for hepatocellular carcinoma: What can we target? Nature Reviews Clinical Oncology, 2020. 17(7), 409–423. https://doi.org/10.1038/s41571-020-0377-8
Forner, A., Reig, M., & Bruix, J. Hepatocellular carcinoma. The Lancet, 2018. 391(10127), 1301–1314. https://doi.org/10.1016/S0140-6736(18)30010-2
Guichard, C., Amaddeo, G., Imbeaud, S., & Letouzé, E. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nature Genetics, 2019. 44(6), 694–698. https://doi.org/10.1038/ng.2256
He, G., & Karin, M. NF-κB and STAT3 – Key players in liver cancer. Cell Research, 2019. 29(8), 574–586. https://doi.org/10.1038/cr.2019.32
Hoshida, Y., Villanueva, A., Kobayashi, M., Peix, J., & Chiang, D. Y. Gene expression in hepatocellular carcinoma. Cancer Research, 2017. 78(2), 250–257. https://doi.org/10.1158/0008-5472.CAN-17-1725
Ikeda, M., Sung, M. W., Kudo, M., et al. Atezolizumab plus bevacizumab in hepatocellular carcinoma. New England Journal of Medicine, 2021. 383(24), 2424–2434. https://doi.org/10.1056/NEJMoa1915745
Kudo, M. Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2025. Oncology, 2019. 97(Suppl 1), 131–141. https://doi.org/10.1159/000503045
Lee, J. S., & Thorgeirsson, S. S. Genetic profiling of hepatocellular carcinoma: Classification and prognosis. Hepatology, 2019. 70(4), 1419–1432. https://doi.org/10.1002/hep.30878
Lin, D. C., Mayakonda, A., Dinh, H. Q., et al. Genomic and epigenomic heterogeneity of hepatocellular carcinoma. Cancer Research, 2020. 80(10), 1914–1925. https://doi.org/10.1158/0008-5472.CAN-19-1725
Llovet, J. M., Kelley, R. K., Villanueva, A., et al. Molecular pathogenesis and systemic therapies for hepatocellular carcinoma. Nature Reviews Clinical Oncology, 2021. 18(10), 595–613. https://doi.org/10.1038/s41571-021-00574-6
Mak, L. Y., Cruz-Ramón, V., Chinchilla-López, P., et al. Global epidemiology, prevention, and management of hepatocellular carcinoma. The American Journal of Gastroenterology, 2021. 116(3), 457–478. https://doi.org/10.14309/ajg.0000000000001051
Sherman, M. Hepatocellular carcinoma: Screening and diagnosis. Clinical Liver Disease, 2018. 22(1), 61–74. https://doi.org/10.1002/cld.784
Sun, H. C., Zhuang, P. Y., Qin, L. X., et al. VEGF and hepatocellular carcinoma angiogenesis. Journal of Cancer Research and Clinical Oncology, 2020. 146(6), 1517–1526. https://doi.org/10.1007/s00432-020-03172-y
Tang, Z. Y. Hepatocellular carcinoma – Causes, diagnosis, and treatment. The Lancet Oncology, 2018. 19(11), 1300–1312. https://doi.org/10.1016/S1470-2045(18)30337-0
Villanueva, A. p53 mutations and liver cancer progression. Hepatology, 2021. 74(2), 1047–1056. https://doi.org/10.1002/hep.31783
Yang, J. D., Hainaut, P., Gores, G. J., et al. A global view of hepatocellular carcinoma: Trends, risk, prevention, and management. Nature Reviews Gastroenterology & Hepatology, 2018. 16(10), 589–604. https://doi.org/10.1038/s41575-019-0186-y
Article Statistics
Copyright License
Copyright (c) 2025 Musaboev E.I, Abdikhakimov A.N, Mirzaev Kh.M, Gafur-Akhunov M.A, Nishanov D.A, Yigitaliyev A.B
This work is licensed under a Creative Commons Attribution 4.0 International License.